Supporting Information

KI- catalyzed reaction of aryl hydrazines with $\alpha$-oxocarboxylic acids
in the presence of CO$_2$: access to 1,3,4-oxadiazol-2(3H)-ones

Na Yang, Hao Zhang and Gaoqing Yuan*
Key Laboratory of Functional Molecular Engineering of Guangdong Province, School of Chemistry and Chemical Engineering, South China University of Technology
Guangzhou 510640, China
E-mail: gqyuan@scut.edu.cn

List of contents

1. General methods.................................................................S2
2. General procedure for the synthesis of 1,3,4-oxadiazol-2(3H)-one.............S2
3. General procedure for $\alpha$-oxocarboxylic acids........................................S2
4. Characterization data ........................................................................S3
5. Reference ....................................................................................S11
6. NMR spectra ..............................................................................S12
1. General methods

$^1$H and $^{13}$C NMR spectra were recorded by using a Bruker DRX-400 spectrometer and CDCl$_3$ as the solvent. The chemical shifts were referenced to signals at 7.26 and 77.23 ppm, respectively. Mass spectra were recorded on a Thermo Scientific ISQ gas chromatograph-mass spectrometer. The data of HRMS were obtained on a high resolution mass spectrometer (LCMS-IT-TOF). Melting points were determined with a Büchi Melting Point B-545 instrument.

2. General procedure for the synthesis of 1,3,4-oxadiazol-2(3$H$)-one

In a typical procedure, phenylhydrazine 1a (0.5 mmol), 2-oxo-2-phenylacetic acid 2a (0.5 mmol), KI (0.2 equiv.), TBHP (4.0 equiv. 70% in water) and K$_2$CO$_3$ (2 equiv.) were dissolved in 5 mL MeOH in a dried 15 mL polyterafluoroethylene (PTFE) reaction vessel. The vessel was fixed into a stainless-steel autoclave with a pressure regulating system. Then the autoclave was sealed and CO$_2$ was introduced from a cylinder. The reaction was carried out at the selected temperature under magnetic stirring for 4.5 h and the pressure was kept constant during the reaction. After the reaction was completed, the vessel was cooled and the pressure was released slowly to atmospheric pressure. Then reaction mixture was diluted with H$_2$O (20 mL) and extracted with EtOAc (15 mL×3). The combined organic layer was dried over anhydrous MgSO$_4$ and then filtered. The solvent was removed under vacuo and the crude product was separated by column chromatography on a silica gel column using petroleum ether/ethyl acetate as eluent to give the desired product 3 or 4.

3. General procedure for α-oxocarboxylic acids$^1$

The substituted α-oxocarboxylic acids (2a–2j) were prepared by oxidation of corresponding methyl ketones with SeO$_2$ (Scheme S1). Methyl ketones (5 mmol), SeO$_2$ (6 mmol), 20 mL of pyridine were added in a 50 mL round-bottom flask. The reaction mixture was stirred at 110 °C for 1 h, then reduce the temperature to 90 °C for 4 h. The desired products (2a–2j) were isolated by silica-gel column chromatography.
in excellent yields (65–90%).

![Scheme S1](image)

**Scheme S1** Preparation of α-oxocarboxylic acids.

4. Characterization data

3,5-diphenyl-1,3,4-oxadiazol-2(3H)-one (3a)

White solid, mp 109–110°C; $^1$H NMR (400 MHz, CDCl$_3$): δ (ppm) 7.83 (t, $J$ = 7.4 Hz, 4H), 7.42 – 7.33 (m, 5H), 7.16 (t, $J$ = 7.4 Hz, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$): δ (ppm) 153.7, 150.8, 136.2, 132.1, 129.3, 129.2, 126.3, 126.1, 123.6, 118.4.

3-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3b)

White solid, mp 148–150 °C; $^1$H NMR (400 MHz, CDCl$_3$): δ (ppm) 7.92 (td, $J$ = 6.8, 3.1 Hz, 4H), 7.55 – 7.49 (m, 3H), 7.18 – 7.13 (m, 2H); $^{13}$C NMR (100 MHz, CDCl$_3$): δ (ppm) 160.8 (d, $J$ = 244.7 Hz), 153.8, 150.9, 132.1, 129.3, 126.2, 123.5, 120.4 (d, $J$ = 8.2 Hz), 116.2 (d, $J$ = 22.8 Hz).

3-(4-chlorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3c)

White solid, mp 143–145 °C; $^1$H NMR (400 MHz, CDCl$_3$): δ (ppm) 7.91 (t, $J$ = 8.3 Hz, 4H), 7.55 – 7.48 (m, 3H), 7.42 (d, $J$ = 8.9 Hz, 2H); $^{13}$C NMR (100 MHz, CDCl$_3$): δ (ppm) 153.9, 150.6, 134.8, 132.3, 131.7, 129.5, 129.3, 126.2, 123.4, 119.6.

3-(4-bromophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3d)
White solid, mp 135–137 °C; **\(^1\)H NMR** (400 MHz, CDCl\(_3\)): δ (ppm) 7.91 (d, \(J = 7.1\) Hz, 2H), 7.83 (d, \(J = 8.9\) Hz, 2H), 7.56 – 7.47 (m, 5H); **\(^{13}\)C NMR** (100 MHz, CDCl\(_3\)): δ (ppm) 153.9, 150.5, 135.3, 132.4, 129.3, 126.2, 123.4, 119.8, 119.4.

5-phenyl-3-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3\(H\))-one (3e)

White solid, mp 111–113 °C; **\(^1\)H NMR** (400 MHz, CDCl\(_3\)): δ (ppm) 8.05 (d, \(J = 8.4\) Hz, 2H), 7.89 (d, \(J = 7.1\) Hz, 2H), 7.67 (d, \(J = 8.5\) Hz, 2H), 7.55 – 7.45 (m, 3H); **\(^{13}\)C NMR** (100 MHz, CDCl\(_3\)): δ (ppm) 154.1, 150.4, 138.9, 132.4, 129.3 (q, \(J = 87.8\) Hz), 129.2, 126.6 (q, \(J = 3.7\) Hz), 126.2, 124.0 (q, \(J = 273.6\) Hz), 123.1, 117.9; **HRMS** (ESI) \(m/z\): calcd for C\(_{15}\)H\(_9\)F\(_3\)N\(_2\)NaO\(_2\) [M+Na]\(^+\) 329.0508, found 329.0509.

4-(2-oxo-5-phenyl-1,3,4-oxadiazol-3(2\(H\))-yl)benzonitrile (3f)

Brown solid, mp 165–167 °C; **\(^1\)H NMR** (400 MHz, CDCl\(_3\)): δ (ppm) 8.10 (d, \(J = 8.8\) Hz, 2H), 7.93 – 7.91 (m, 2H), 7.73 (d, \(J = 8.8\) Hz, 2H), 7.55 (dd, \(J = 18.0, 7.5\) Hz, 3H); **\(^{13}\)C NMR** (100 MHz, CDCl\(_3\)): δ (ppm) 174.8, 154.4, 150.2, 139.5, 133.5, 129.3, 126.3, 122.9, 118.2, 109.3.

3-(4-nitrophenyl)-5-phenyl-1,3,4-oxadiazol-2(3\(H\))-one (3g)

Brown solid, mp 167–169 °C; **\(^1\)H NMR** (400 MHz, CDCl\(_3\)): δ (ppm) 8.32 (d, \(J = 7.9\) Hz, 2H), 8.16 (d, \(J = 7.7\) Hz, 2H), 7.94 (d, \(J = 6.3\) Hz, 2H), 7.56 (dd, \(J = 18.0, 6.6\) Hz, 3H); **\(^{13}\)C NMR** (100 MHz, CDCl\(_3\)): δ (ppm) 154.6, 150.2, 145.1, 141.0, 132.8, 129.4, 126.4, 125.2, 122.8, 118.0.
5-phenyl-3-(p-tolyl)-1,3,4-oxadiazol-2(3H)-one (3h)

White solid, mp 154-156°C; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.91 (d, \( J = 8.2 \) Hz, 2H), 7.79 (d, \( J = 8.5 \) Hz, 2H), 7.51 – 7.46 (m, 3H), 7.24 (d, \( J = 8.6 \) Hz, 2H), 2.36 (s, 3H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 153.5, 150.9, 136.1, 133.8, 132.0, 129.9, 129.2, 126.1, 123.7, 118.5, 21.1.

3-(4-isopropylphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3i)

Brown oil; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.93 (dd, \( J = 8.1, 1.4 \) Hz, 2H), 7.85 – 7.81 (m, 2H), 7.53 – 7.47 (m, 3H), 7.32 (d, \( J = 8.6 \) Hz, 2H), 2.94 (dt, \( J = 13.8, 6.9 \) Hz, 1H), 1.28 (s, 3H), 1.26 (s, 3H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 153.6, 151.0, 147.3, 134.0, 132.0, 129.2, 127.3, 126.1, 118.8, 33.9, 24.1; HRMS (ESI) m/z: calcld for C_{17}H_{16}N_{2}O_{2} [M+Na]\textsuperscript{+} 303.1104, found 303.1102.

3-(4-methoxyphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3j)

White solid, mp 138–140 °C; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.92 (dd, \( J = 8.0, 1.4 \) Hz, 2H), 7.83 – 7.80 (m, 2H), 7.53 – 7.47 (m, 3H), 6.98 – 6.96 (m, 2H), 3.82 (s, 3H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 158.1, 153.5, 151.1, 132.0, 129.5, 129.2, 126.1, 123.8, 120.4, 114.5, 55.7.

3-(2-fluorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3k)
Brown solid, mp 101–103 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.91 (d, J = 7.7 Hz, 2H), 7.59 (t, J = 7.7 Hz, 1H), 7.51 (dt, J = 14.7, 7.4 Hz, 3H), 7.42 (dd, J = 12.9, 7.6 Hz, 1H), 7.26 (dd, J = 12.3, 7.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 156.6 (d, J = 253.5 Hz), 154.7, 151.7, 132.2, 130.7 (d, J = 7.7 Hz), 129.2, 127.1, 126.1, 124.9 (d, J = 3.9 Hz), 123.6, 123.1 (d, J = 11.6 Hz), 117.3 (d, J = 19.2 Hz); HRMS (ESI) m/z: calcd for C₁₄H₁₀FN₂O₂ [M+H]⁺ 257.0721, found 257.0717.

3-(2-chlorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3l)

White solid, mp 121–123 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.91 (d, J = 7.6 Hz, 2H), 7.55 (s, 2H), 7.50 (dd, J = 13.9, 6.6 Hz, 3H), 7.43 – 7.41 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 154.5, 151.9, 132.6, 132.2, 132.1, 131.1, 131.0, 129.2, 129.1, 128.0, 126.1, 123.7. HRMS (ESI) m/z: calcd for C₁₄H₁₀ClN₂O₂ [M+H]⁺ 273.0425, found 273.0419.

3-(2-bromophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3m)

Brown solid, mp 123–125 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.93 (d, J = 7.4 Hz, 2H), 7.75 (d, J = 8.0 Hz, 1H), 7.51 (ddd, J = 20.6, 13.4, 7.7 Hz, 5H), 7.37 (t, J = 7.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 154.4, 151.8, 134.2, 134.2, 132.2, 131.5, 129.5, 129.3, 128.7, 126.1, 123.7, 121.8; HRMS (ESI) m/z: calcd for C₁₄H₁₀BrN₂O₂ [M+H]⁺ 316.9920, found 316.9912.

3-(3-bromophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3n)

White solid, mp 125–127 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 8.12 (t, J = 1.9 Hz, 1H), 7.93 (dt, J = 8.4, 1.7 Hz, 3H), 7.55 – 7.48 (m, 3H), 7.39 (dd, J = 8.0, 1.6 Hz,
1H), 7.31 (t, J = 8.1 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 154.0, 150.5, 137.3, 132.4, 130.7, 129.3, 129.2, 126.2, 123.3, 123.1, 121.3, 116.7; HRMS (ESI) m/z: calcld for C14H10BrN2O2 [M+H]+ 316.9920, found 316.9916.

5-phenyl-3-(m-tolyl)-1,3,4-oxadiazol-2(3H)-one (3o)

Brown solid, mp 99–101 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.94 (dd, J = 8.1, 1.5 Hz, 2H), 7.75 (d, J = 12.0 Hz, 2H), 7.54 – 7.47 (m, 3H), 7.34 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 2.42 (s, 3H); 13C NMR (100 MHz, CDCl3): δ (ppm) 153.7, 150.9, 139.5, 136.2, 132.1, 129.2, 127.2, 126.2, 123.7, 119.1, 115.7, 21.8. HRMS (ESI) m/z: calcld for C15H13N2O2 [M+H]+ 253.0972, found 253.0968.

5-phenyl-3-(o-tolyl)-1,3,4-oxadiazol-2(3H)-one (3p)

Brown solid, mp 107–109 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.91 (d, J = 6.8 Hz, 2H), 7.52 (dd, J = 10.9, 7.2 Hz, 3H), 7.43 (d, J = 7.4 Hz, 1H), 7.36 – 7.32 (m, 3H), 2.38 (s, 3H); 13C NMR (100 MHz, CDCl3): δ (ppm) 154.2, 152.3, 135.3, 134.0, 132.0, 131.7, 129.7, 129.2, 127.1, 126.7, 126.0, 123.9, 18.3. HRMS (ESI) m/z: calcld for C15H13N2O2 [M+H]+ 253.0972, found 253.0966.

3-(3-chloro-4-fluorophenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3q)

Brown solid, mp 126–128 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 8.04 (d, J = 4.1 Hz, 1H), 7.90 (dd, J = 24.2, 8.1 Hz, 3H), 7.53 (dt, J = 14.2, 6.9 Hz, 3H), 7.22 (d, J = 8.5 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 156.2 (d, J = 247.4 Hz), 154.1, 150.5, 132.8 (d, J = 3.2 Hz), 132.5, 129.3, 126.3, 123.3, 122.0 (d, J = 18.9 Hz), 120.7, 118.0 (d, J = 7.1 Hz), 117.2 (d, J = 22.2 Hz); HRMS (ESI) m/z: calcld for C15H13ClFN2NaO2 [M+Na]+ 313.0151, found 313.0150.

3-(3-chloro-4-methylphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3r)

[57]
White solid, mp 152–154 °C; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.60 (dd, \( J = 177.9, 75.8 \) Hz, 8H), 2.35 (s, 3H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 153.8, 150.5, 135.1, 134.9, 134.0, 132.2, 131.4, 129.2, 126.1, 123.4, 118.8, 116.3, 19.7; HRMS (ESI) \( m/z \): calcd for C\textsubscript{15}H\textsubscript{11}ClN\textsubscript{2}NaO\textsubscript{2} [M+Na]\textsuperscript{+} 309.0401, found 309.0403.

3-(3,5-dimethylphenyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one (3s)

Brown oil; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.94 (d, \( J = 6.9 \) Hz, 2H), 7.56 – 7.48 (m, 5H), 6.91 (s, 1H), 2.38 (s, 6H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 153.6, 151.0, 139.3, 136.1, 132.1, 129.2, 128.1, 126.1, 123.7, 116.3, 21.7; HRMS (ESI) \( m/z \): calcd for C\textsubscript{16}H\textsubscript{14}N\textsubscript{2}NaO\textsubscript{2} [M+Na]\textsuperscript{+} 289.0947, found 289.0949.

5-(4-fluorophenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4a)

White solid, mp 141–143 °C; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.95 – 7.91 (m, 4H), 7.46 (t, \( J = 8.0 \) Hz, 2H), 7.29 – 7.25 (m, 1H), 7.19 (t, \( J = 8.6 \) Hz, 2H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 165.1 (d, \( J = 252.2 \) Hz), 153.0, 150.7, 136.2, 129.4, 128.5 (d, \( J = 8.9 \) Hz), 126.4, 120.0 (d, \( J = 3.2 \) Hz), 118.5, 116.7 (d, \( J = 8.6 \) Hz).

5-(4-chlorophenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4b)

White solid, mp 136–138 °C; \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}): \( \delta \) (ppm) 7.92 (d, \( J = 8.0 \) Hz, 2H), 7.86 (d, \( J = 8.4 \) Hz, 2H), 7.46 (t, \( J = 9.4 \) Hz, 4H), 7.28 (t, \( J = 7.7 \) Hz, 1H); \textsuperscript{13}C
NMR (100 MHz, CDCl₃): δ (ppm) 152.9, 150.6, 138.5, 136.1, 129.7, 129.4, 127.4, 126.5, 122.1, 118.5.

5-(4-bromophenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4c)

White solid, mp 124–126 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.92 (d, J = 8.2 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.47 (t, J = 7.7 Hz, 2H), 7.28 (dd, J = 13.5, 6.1 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 153.1, 150.7, 136.2, 132.7, 129.5, 127.6, 126.9, 126.5, 122.6, 118.6.

3-phenyl-5-(p-tolyl)-1,3,4-oxadiazol-2(3H)-one (4d)

White solid, mp 149–151 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.93 (d, J = 8.1 Hz, 2H), 7.81 (d, J = 8.1 Hz, 2H), 7.47 (s, 2H), 7.30 – 7.24 (m, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 153.9, 150.9, 142.8, 136.3, 129.9, 129.4, 126.2, 126.1, 120.9, 118.4, 21.9.

5-(4-methoxyphenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4e)

White solid, mp 143–145 °C; ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.92 (d, J = 7.8 Hz, 2H), 7.85 (d, J = 8.9 Hz, 2H), 7.45 (t, J = 8.0 Hz, 2H), 7.25 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 8.9 Hz, 2H), 3.84 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ (ppm) 162.7, 153.7, 150.9, 142.8, 136.3, 129.3, 127.9, 126.1, 118.3, 116.0, 114.7, 55.6.

5-(3-chlorophenyl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4f)
White solid, mp 107–109 °C; $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ (ppm) 7.93 (d, $J = 7.9$ Hz, 3H), 7.82 (d, $J = 7.3$ Hz, 1H), 7.47 (dt, $J = 17.5$, 8.8 Hz, 4H), 7.29 (t, $J = 7.5$ Hz, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ (ppm) 152.6, 150.6, 136.1, 135.5, 132.2, 130.6, 129.5, 126.6, 126.2, 125.3, 124.2, 118.5; HRMS (ESI) $m/z$: calcd for C$_{14}$H$_9$ClN$_2$NaO$_2$ [M+Na]$^+$, 295.0245, found 295.0239.

3-phenyl-5-(m-tolyl)-1,3,4-oxadiazol-2(3H)-one (4g)$^2$

White solid, mp 126–128 °C; $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ (ppm) 7.93 (d, $J = 8.1$ Hz, 2H), 7.74 – 7.70 (m, 2H), 7.45 (t, $J = 7.9$ Hz, 2H), 7.38 – 7.31 (m, 2H), 7.26 (t, $J = 6.8$ Hz, 1H), 2.41 (s, 3H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ (ppm) 153.9, 150.9, 139.1, 136.3, 132.9, 129.4, 129.1, 126.6, 126.2, 123.5, 123.3, 118.4, 21.5.

3-phenyl-5-(o-tolyl)-1,3,4-oxadiazol-2(3H)-one (4h)$^2$

White solid, mp 95–97 °C; $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ (ppm) 7.95 (d, $J = 8.3$ Hz, 2H), 7.86 (d, $J = 7.9$ Hz, 1H), 7.44 (dt, $J = 19.9$, 7.5 Hz, 3H), 7.34 – 7.25 (m, 3H), 2.69 (s, 3H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ (ppm) 154.1, 150.6, 138.3, 136.4, 132.1, 131.6, 129.4, 128.4, 126.5, 126.2, 122.3, 118.4, 22.4.

5-(furan-2-yl)-3-phenyl-1,3,4-oxadiazol-2(3H)-one (4i)$^3$

Brown solid, mp 106–108 °C; $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ (ppm) 7.92 (d, $J = 8.1$ Hz, 2H), 7.65 (s, 1H), 7.46 (t, $J = 7.9$ Hz, 2H), 7.30 – 7.26 (m, 1H), 7.09 (d, $J = 3.4$ Hz, 1H), 6.61 – 6.60 (m, 1H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ (ppm) 150.0, 147.1, 146.2, 138.8, 136.1, 129.4, 126.5, 118.5, 114.7, 112.3.
3-phenyl-5-(thiophen-2-yl)-1,3,4-oxadiazol-2(3H)-one (4j)

Brown solid, mp 134–136 °C; \( ^1H \text{ NMR} \) (400 MHz, CDCl\(_3\)): \( \delta \) (ppm) 7.91 (d, \( J = 7.9 \) Hz, 2H), 7.68 (s, 1H), 7.55 (d, \( J = 4.6 \) Hz, 1H), 7.45 (t, \( J = 7.6 \) Hz, 2H), 7.27 (t, \( J = 6.5 \) Hz, 1H), 7.15 (s, 1H); \( ^{13}C \text{ NMR} \) (100 MHz, CDCl\(_3\)): \( \delta \) (ppm) 150.6, 150.3, 136.1, 130.4, 130.1, 129.4, 128.3, 126.4, 125.2, 118.5.

methyl 1,3-diphenyl-4,5-dihydro-1H-pyrazole-5-carboxylate (5a)

White solid, mp 97–99 °C; \( ^1H \text{ NMR} \) (400 MHz, CDCl\(_3\)): \( \delta \) 7.67 (d, \( J = 7.0 \) Hz, 2H), 7.36 – 7.23 (m, 5H), 7.09 (d, \( J = 7.7 \) Hz, 2H), 6.85 (t, \( J = 6.9 \) Hz, 1H), 4.75 (dd, \( J = 12.4, 6.4 \) Hz, 1H), 3.69 (s, 3H), 3.62 – 3.52 (m, 1H), 3.35 (dd, \( J = 17.0, 6.3 \) Hz, 1H); \( ^{13}C \text{ NMR} \) (100 MHz, CDCl\(_3\)): \( \delta \) 172.1, 147.1, 144.7, 132.1, 129.3, 129.0, 128.7, 126.0, 119.9, 113.0, 61.7, 52.8, 38.3; HRMS (ESI) m/z: calcd for C\(_{17}\)H\(_{17}\)N\(_2\)O\(_2\) [M+Na]\(^+\), 281.1285, found 281.1286.

5. Reference

6. NMR spectra

3a
3b
3f
S29
4b